Filed Pursuant to Rule 424(b)(3)
Registration No. 333-14010
TEVA PHARMACEUTICAL FINANCE N.V.
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
SUPPLEMENT NO. 9 DATED JULY 25, 2003
TO
PROSPECTUS DATED NOVEMBER 14, 2001
AS SUPPLEMENTED
BY
SUPPLEMENT NO. 1 DATED NOVEMBER 28, 2001,
SUPPLEMENT NO. 2 DATED JANUARY 15, 2002,
SUPPLEMENT NO. 3 DATED MARCH 22, 2002,
SUPPLEMENT NO. 4 DATED APRIL 25, 2002,
SUPPLEMENT NO. 5 DATED SEPTEMBER 11, 2002,
SUPPLEMENT NO. 6 DATED OCTOBER 9, 2002,
SUPPLEMENT NO. 7 DATED OCTOBER 23, 2002
AND
SUPPLEMENT NO. 8 DATED JUNE 18, 2003
This supplement is part of and should be read in conjunction with our
prospectus dated November 14, 2001, as supplemented by Supplement No. 1 dated
November 28, 2001, Supplement No. 2 dated January 15, 2002, Supplement No. 3
dated March 22, 2002, Supplement No. 4 dated April 25, 2002, Supplement No. 5
dated September 11, 2002, Supplement No. 6 dated October 9, 2002, Supplement No.
7 dated October 23, 2002 and Supplement No. 8 dated June 18, 2003 (as
supplemented, the "Prospectus"). The information we present in this supplement
supersedes similar information included in the Prospectus.
We are supplementing the information under the caption "Selling
Securityholders" to include a new Selling Securityholder and the number of
Debentures and ADRs owned and offered thereby:
- --------------------------------------------------------------------------------------------------------------------------------
Principal
Amount of
Debentures
ADRs Beneficially Owned Owned and ADRs Beneficially Owned
Before Offering (1)(2) Offered ADRs After Offering (2)
Name and Address of Selling ----------------------- Hereby Offered -----------------------
Securityholder Amount Percentage(3) (in $1,000s) Hereby (1) Amount Percentage (3)
- --------------------------- ----- ------------- ------------ ---------- ------ --------------
Jeffries & Co. Inc. 2,330 * 100 2,330 0 N/A
Harborside Financial Center
Suite 705, Plaza III
Jersey City, New Jersey 07311
- --------------------------------------------------------------------------------------------------------------------------------
(1) Assumes conversion of all of the selling securityholder's Debentures at a conversion rate of 23.3036 ADRs per each $1,000
principal amount of debentures (rounded down to the nearest whole ADR) ), which gives effect of the 2-for-1 Teva ordinary share
split effected December 10, 2002 (and the related split of ADRs of Teva).
(2) Includes, if applicable, conversion of all the selling securityholder's Teva Pharmaceutical Finance, LLC 1.50% Convertible
Senior Debentures due 2005 at a conversion rate of 23.1934 ADRs per each $1,000 principal amount of debentures (rounded down to
the nearest whole ADR) ), which gives effect of the 2-for-1 Teva ordinary share split effected December 10, 2002 (and the related
split of ADRs of Teva). Also includes, if applicable, conversion of all the selling security holder's Teva Pharmaceutical Finance
B.V. 0.375% Convertible Sensor Debentures due 2022 at a conversion rate of 23.3106 ADRs per each $1,000 principal amount of
debentures (rounded down to the nearest whole ADR), which gives effect of the 2-for-1 Teva ordinary share split effected December
10, 2002 (and the related split of ADRs of Teva).
(3) Except as noted, assumes that Debentures held by other holders are not converted.
* Less than 1%